These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38315170)

  • 1. Polycomb repressor complex 2 suppresses interferon-responsive MHC-II expression in melanoma cells and is associated with anti-PD-1 resistance.
    James JL; Taylor BC; Axelrod ML; Sun X; Guerin LN; Gonzalez-Ericsson PI; Wang Y; Sanchez V; Fahey CC; Sanders ME; Xu Y; Hodges E; Johnson DB; Balko JM
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38315170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.
    Yang Z; Li F; Huang Y; Yin N; Chu J; Ma Y; Pettigrew RI; Hamilton DJ; Martin DR; Li Z
    J Nucl Med; 2022 Nov; 63(11):1708-1714. PubMed ID: 35210298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids.
    Pickles OJ; Wanigasooriya K; Ptasinska A; Patel AJ; Robbins HL; Bryer C; Whalley CM; Tee L; Lal N; Pinna CMA; Elzefzafy N; Taniere P; Beggs AD; Middleton GM
    Cancer Res Commun; 2023 Aug; 3(8):1501-1513. PubMed ID: 37565053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZH2: an emerging role in melanoma biology and strategies for targeted therapy.
    Tiffen J; Gallagher SJ; Hersey P
    Pigment Cell Melanoma Res; 2015 Jan; 28(1):21-30. PubMed ID: 24912396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycomb recruitment at the Class II transactivator gene.
    Boyd NH; Morgan JE; Greer SF
    Mol Immunol; 2015 Oct; 67(2 Pt B):482-91. PubMed ID: 26283540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
    Zingg D; Arenas-Ramirez N; Sahin D; Rosalia RA; Antunes AT; Haeusel J; Sommer L; Boyman O
    Cell Rep; 2017 Jul; 20(4):854-867. PubMed ID: 28746871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
    Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma.
    Tiffen J; Gallagher SJ; Filipp F; Gunatilake D; Emran AA; Cullinane C; Dutton-Register K; Aoude L; Hayward N; Chatterjee A; Rodger EJ; Eccles MR; Hersey P
    J Invest Dermatol; 2020 Dec; 140(12):2442-2454.e5. PubMed ID: 32360600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
    Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
    Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
    Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
    J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
    Hoffmann F; Zarbl R; Niebel D; Sirokay J; Fröhlich A; Posch C; Holderried TAW; Brossart P; Saavedra G; Kuster P; Strieth S; Gielen GH; Ring SS; Dietrich J; Pietsch T; Flatz L; Kristiansen G; Landsberg J; Dietrich D
    Clin Epigenetics; 2020 Jun; 12(1):94. PubMed ID: 32586358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
    Johnson DB; Estrada MV; Salgado R; Sanchez V; Doxie DB; Opalenik SR; Vilgelm AE; Feld E; Johnson AS; Greenplate AR; Sanders ME; Lovly CM; Frederick DT; Kelley MC; Richmond A; Irish JM; Shyr Y; Sullivan RJ; Puzanov I; Sosman JA; Balko JM
    Nat Commun; 2016 Jan; 7():10582. PubMed ID: 26822383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells.
    Radosevich M; Song Z; Gorga JC; Ksander B; Ono SJ
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):3185-95. PubMed ID: 15326139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
    Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
    Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma.
    Holling TM; Bergevoet MW; Wilson L; Van Eggermond MC; Schooten E; Steenbergen RD; Snijders PJ; Jager MJ; Van den Elsen PJ
    J Immunol; 2007 Oct; 179(8):5317-25. PubMed ID: 17911618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.
    Rodríguez T; Méndez R; Del Campo A; Aptsiauri N; Martín J; Orozco G; Pawelec G; Schadendorf D; Ruiz-Cabello F; Garrido F
    Immunogenetics; 2007 Feb; 59(2):123-33. PubMed ID: 17180681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression.
    Fan T; Jiang S; Chung N; Alikhan A; Ni C; Lee CC; Hornyak TJ
    Mol Cancer Res; 2011 Apr; 9(4):418-29. PubMed ID: 21383005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
    Luo N; Formisano L; Gonzalez-Ericsson PI; Sanchez V; Dean PT; Opalenik SR; Sanders ME; Cook RS; Arteaga CL; Johnson DB; Balko JM
    Oncoimmunology; 2018; 7(6):e1438106. PubMed ID: 29872580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.